# IBEX Limited (IBEX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Technology / Software. Price $39.17, market value $524 million.

## Valuation
- **P/E (trailing): 12.2×** (5-yr avg 15.2×, 3-yr avg 11.3×). IBEX Limited trades at 12.2× trailing earnings, close to its own five-year average of 15.2×. The Technology median in the September 2026 study was 32.1×. Forward P/E is 10.8×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.38**. A PEG of 0.38 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 0.8×**. Each dollar of revenue is priced at 0.8×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 3.3×**. The shares trade at 3.3× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 6.7×**. Enterprise value is 6.7× operating earnings before depreciation, the multiple that ignores how the company is financed; below 8× is inexpensive for most sectors.
- **Free-cash-flow yield: 6.2%** (5-yr avg 4.8%). Free cash flow equals 6.2% of the market value, above its five-year average of 4.8%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 8.2%**. The inverse of the P/E: 8.2% of the price is earned each year.

## Profitability
- **Operating margin: 9.2%**. 9.2% of revenue is left after running the business.
- **Net margin: 6.6%**. 6.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 27.4%**. 27.4% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 37.9%**. Return on all capital, debt included, is 37.9%: comfortably above what that capital costs.
- **Return on assets: 17.3%**. Each dollar of assets produces 17.3% of profit.

## Growth
- **Revenue growth (1 yr): 9.8%** (3-yr 4.2%/yr, 5-yr 6.6%/yr). Revenue grew 9.8% over the last year, against 6.6% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 28.3%** (3-yr 27.1%/yr). Earnings per share rose 28.3%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 24.7%/yr**. Free cash flow has compounded at 24.7% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.01**. Debt is 0.01 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. IBEX Limited holds more cash than debt.
- **Altman Z-score: 5.56**. A Z-score of 5.56 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. IBEX Limited does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 33.2%** (YTD 2.6%, 3-mo 30.8%). The shares are up 33.2% over twelve months including dividends.
- **From 52-week high: -8.9%** (51.0% above the low). Trading 9% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 67**. An RSI of 67 is neutral.
- **Beta (1 yr): 0.67** (volatility 52%). Beta of 0.67 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IBEX · Page: https://foliofundamentals.com/stocks/ibex

Not investment advice.